GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Gallup's July 7, 2026 poll release documented the first large-population evidence that GLP-1 uptake is bending the US obesity curve: 11% of US adults now take a GLP-1 for weight loss (up from 3% in 2024 and 8% in 2025), and the US adult obesity rate has drifted from a 2022 peak of 39.9% down to 36.4% in 2026. Awareness climbed from 80% to 91% over the same span. Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
Boehringer Ingelheim announced Thursday July 16, 2026 the start of a Phase 2 clinical trial evaluating BI 3034701, its investigational triple GLP-1/GIP/NPY2 receptor agonist peptide, in patients with obesity and overweight. BI 3034701 is a potential first-in-class triple agonist designed to activate three complementary biological pathways: GLP-1 and GIP receptors reduce appetite and regulate metabolism, and the neuropeptide Y2 (NPY2) receptor modulates central hunger signaling. Phase 1 studies previously showed a generally favorable safety and tolerability profile that supported advancing the program. BI 3034701 is based on Gubra-discovered technology and licensed to Boehringer Ingelheim, which is responsible for global clinical development and commercialization. The program adds a distinct third target to the emerging next-generation obesity landscape: Eli Lilly's retatrutide (GLP-1/GIP/glucagon triple agonist in TRIUMPH Phase 3), Novo Nordisk's UBT251 (GLP-1/GIP/glucagon triple in Phase 1/2a), and Boehringer's dual glucagon/GLP-1 survodutide (Phase 3, 16.6% weight loss in obesity). The NPY2 receptor target is novel to the class and could carry a distinct safety and tolerability profile alongside the incretin-plus-incretin backbone.
Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, presented at the 4th Annual Obesity & Weight Loss Drug Development Summit in Boston, Massachusetts on Tuesday July 14, 2026. Gary Barnette, PhD, Chief Scientific Officer, led the pre-conference workshop 'Moving Beyond BMI & Weight-Loss Endpoints to Advance the Regulatory Frontier & Redefine Clinical Success With the FDA' at 1:30 PM ET. On Wednesday July 15 at 4:20 PM ET, Chairman, President and CEO Mitchell Steiner, MD will present 'Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s With Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss.' Veru's lead asset enobosarm is a selective androgen receptor modulator (SARM) in Phase 2b development for muscle-loss prevention in older patients receiving GLP-1 receptor agonists for weight loss. The sarcopenic-obesity thesis directly addresses a widely documented GLP-1 side effect: approximately 25-40% of GLP-1-associated weight loss is lean muscle mass rather than fat, particularly in older patients. Veru's approach pairs the GLP-1 with a SARM to preserve muscle while maintaining fat loss.
Pfizer (NYSE: PFE) named Danna Breen Vice President and head of obesity discovery on Monday July 13, 2026, following the departure of longtime scientific leader Kendra Bence. Bence had led internal medicine research across metabolic dysfunction-associated steatohepatitis (formerly known as NASH) and obesity discovery at Pfizer's Kendall Square research site for more than a decade, and described the role as 'the absolute privilege of my career' when announcing her exit. Breen advanced through multiple roles at Pfizer including Research Associate, Fellow, Senior Principal Scientist, Principal Scientist, and Senior Scientist, working on novel obesity drug targets and research collaborations. The role transition arrives as Pfizer's obesity portfolio expands substantially: the monthly GLP-1 receptor agonist berobenatide (PF-3944) is advancing through 10 planned Phase 3 studies presented at ADA 2026 in June, and the November 2025 $10 billion Metsera acquisition brought in the amylin peptide MET-233i (positive Phase 1 data supporting monthly dosing). Endpoints News concurrently reported AI startup Xaira making its own leadership adjustments as the sector's talent map continues to reshape.
CNBC Healthy Returns and the Peterson Health Technology Institute (PHTI) documented Wednesday July 8, 2026 that employer coverage of GLP-1 drugs for obesity has held steady at 36% year-over-year despite the Medicare GLP-1 Bridge launching on July 1 and putting downward pressure on the payer landscape. Mercer survey data shows 60% of employers cover GLP-1s for diabetes only, 36% cover for both diabetes and weight loss, 3% don't cover them at all, and 2% are not sure. Rather than expanding coverage, employers pursued alternative approaches: 27% steer workers to direct-to-consumer cash platforms (such as LillyDirect, NovoCare Pharmacy, and telehealth intermediaries), while 21% push workers to use FSA, HSA, or integrated HRA dollars. GoodRx data show the uninsured share for Zepbound rose 18% year-over-year, leaving over 114 million Americans with no commercial coverage for the drug; 88% of those who do have coverage face additional requirements like prior authorization. GLP-1 drugs accounted for 11.4% of annual claims for employers covering them in 2026, up from 6.9% in 2023, sustaining the affordability tension that has kept coverage stuck.
Gallup released Tuesday July 7, 2026 poll results (survey conducted May-June 2026 with 5,000+ respondents across all 50 states and DC) showing 1 in 9 US adults (11%) now take a GLP-1 medication for weight loss. That share tripled from 3% in the 2024 survey and rose from 8% in 2025. The US adult obesity rate, which peaked at 39.9% in 2022, has drifted down to 36.4% in 2026, a statistically significant decline that inversely tracks the rise in GLP-1 use. Awareness of GLP-1 drugs for weight loss climbed from 80% in 2024 to 91% in 2026. Diagnosis of diabetes held steady after 15 years of slow increase in prior surveys. Follow-up coverage ran through Wednesday-Friday (Foreign Policy Journal, Forbes' Zachary Folk, Medscape, Fox 7 Austin, Bakery & Snacks) framing the results as the first large-population evidence that GLP-1 uptake is bending the US obesity curve. Payer analyst commentary tracked in parallel: employers continue steering workers toward cash-pay GLP-1 platforms as sticker prices stay high and adherence remains a concern (roughly two-thirds of non-T2D GLP-1 patients discontinue within one year).
A JAMA study led by a Yale researcher, reported by STAT on July 6, had an investigator pose as a patient across 49 websites selling branded or compounded semaglutide or tirzepatide between August and December 2025. Of those, 45 sites (91.8%) issued a prescription, with a median time to prescription of one day or less and often minimal clinical evaluation. The findings sharpen concerns about telehealth prescribing standards as enforcement against compounded GLP-1s tightens.
Anodyne Nanotech closed a $12.6 million Series A, led by Velocity Partners, to advance ANN-101, a once-weekly GLP-1 skin patch, into first-in-human trials. The Boston company's HeroPatch solid-state microneedle platform delivers multi-milligram doses of peptides without injections or cold storage, aiming to reach the drug exposures obesity treatment requires. The round adds to a wave of investment in alternatives to weekly GLP-1 injections.
The American College of Cardiology, American Heart Association, American Diabetes Association, and American Society of Nephrology jointly published the first-ever clinical guideline for Cardiovascular-Kidney-Metabolic (CKM) Syndrome on June 9, 2026, in Circulation and JACC. The framework establishes a standardized CKM staging system (stages 0 to 4) to identify patients earlier, personalize therapy by absolute cardiovascular risk, and promote both prevention and regression of disease. GLP-1 receptor agonists are explicitly recommended in select patients with type 2 diabetes or obesity plus other cardiovascular risk factors, alongside SGLT2 inhibitors and kidney-protective therapies. The guideline embeds the GLP-1 class into multi-society standard of care for the first time and adds clinical-society weight to the SELECT, FLOW, and ESSENCE outcomes evidence base.
A target trial emulation of more than 160,000 patients, published online June 7, 2026 in Annals of Oncology and presented at ASCO 2026, reported that adults with obesity but without diabetes who received GLP-1 receptor agonists had a 41% lower risk of obesity-associated cancers compared with non-users. Subgroup signals included a 68% reduction in men and a 58% reduction in endometrial cancer. Lead author Arthur Heng-Cheng Hsu (Houston Methodist Neal Cancer Center) and colleagues examined 13 obesity-associated cancers across the TriNetX nationwide database. The findings extend prior signals from the SELECT trial (cardiovascular benefit) and FLOW (kidney benefit) into oncology and add empirical weight behind the 21-expert global panel proposal for a 10-year prospective GLP-1 cancer-prevention trial first surfaced at ECO 2026 in Istanbul.
The Business Group on Health's June 2026 survey of 105 large US employers found 67% currently cover GLP-1 drugs for weight management, but about 10% of those covering plan to drop coverage in 2027 as total spending continues to climb even as per-unit GLP-1 prices have fallen. The Foundayo and Wegovy pill launches drew in patients who had not previously tried GLP-1 therapy, increasing aggregate utilization. Employers that continue covering are layering on management strategies: required participation in a weight-management program, biometric eligibility verification, and restricted prescribing to specific providers. The 2027 employer-coverage cliff is the next financial pressure point for Lilly, Novo, and the pharmacy benefit managers that have built obesity formularies around employer-sponsored plans.
A Stanford-led retrospective pre-post cohort study presented June 13 at ENDO 2026 in Chicago used NIH All of Us Research Program data linking electronic health records with Fitbit activity in 1,950 adults with obesity who started GLP-1 medications. Among the 753 with sufficient wearable data, mean daily steps dropped from 5,047 before GLP-1 initiation to 4,487 after (-560 steps, p<0.001); moderate-to-vigorous activity fell from 27.9 to 22.2 minutes per day (-5.7 minutes, p<0.001). The largest declines occurred in men and in people with pre-existing joint or muscle pain; age, heart failure, and stroke history did not change the pattern. Lead author Surya Maharjan flagged the activity drop as a concern given GLP-1-associated lean-mass loss.
A research team from University Hospitals Coventry and Warwickshire and Warwick Medical School presented meta-analysis data from randomized controlled trials at ENDO 2026 on June 14 showing that 24 weeks of GLP-1 receptor agonist treatment improved testosterone levels, sperm count, and sperm morphology in men ages 18 to 65 with obesity-related low testosterone. Principal investigator Pratibha Natesh proposed reduced inflammation and metabolic stress as candidate mechanisms, with the GLP-1 class potentially preferable to testosterone replacement therapy in this population because TRT can suppress endogenous sperm production. The findings were drawn from men with high BMI, so external validity to normal-weight populations is unclear.
AJMC reported real-world claims data showing that 51.3% of patients on GLP-1 drugs carry at least one diagnosis tied to an emerging GLP-1 indication, 13.8% carry two, and 6.8% carry three or more. Obstructive sleep apnea led the comorbidity prevalence at 25.5%, followed by major depressive disorder at 18.2%, chronic kidney disease at 10.6%, and NAFLD/NASH at 10.3%. The numbers quantify the indication creep the field has been narrating since ADA: prescribers are increasingly writing GLP-1s for patients whose secondary conditions align with the expanding regulatory map (Wegovy CV, FLOW kidney, SURMOUNT-OSA, ESSENCE MASH).
Novo Nordisk presented Phase 2 data for zenagamtide (formerly amycretin), its unimolecular GLP-1 and amylin receptor agonist, at ADA 2026 in 262 adults with type 2 diabetes randomized across six subcutaneous doses (0.4 to 40 mg) versus placebo. The 40 mg arm cut HbA1c by 1.71 percentage points and reduced body weight by 14.6% at 36 weeks, with nearly 89% of patients reaching HbA1c below 7%. The study met its primary HbA1c endpoint across all doses; Novo plans Phase 3 in H2 2026 and hosted a same-day R&D investor event.
5W Public Relations published the fourth installment of its AI Visibility Index, finding two manufacturers — Novo Nordisk and Eli Lilly — account for nearly 100% of GLP-1-class citations inside ChatGPT, Claude, Perplexity, and Google AI Overviews. Five products — Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda — capture about 57% of all weight-loss-and-metabolic-health category citations. Founder Ronn Torossian attributes the citation moat to peer-reviewed clinical data cadence, named-author editorial coverage, and regulatory events treated as content events, with content velocity outpacing the broader news cycle.
Prof. John Wilding (University of Liverpool) and colleagues will present at ECO 2026 a real-world observational study tracking obesity-linked complication rates by degree of GLP-1-driven weight loss. In the year following GLP-1 treatment initiation, 27.0% of patients had BMI reductions <5%, 22.4% had 5-<10%, 14.1% had 10-<15%, 15.8% had ≥15%, and 20.8% gained BMI. Over a mean 11-month follow-up, patients with ≥15% BMI reduction had 37% lower osteoarthritis odds, 30% lower CKD odds, 69% lower OSA odds, and 32% lower heart failure odds versus those with 0-5% reduction (all statistically significant except heart failure). Incidence per 1,000 person-years: 21.4 OA, 21.1 CKD, 20.3 OSA, 3.9 HF. The data quantifies the value of pushing for deeper weight loss rather than cruise-control dosing.
A Nature Communications umbrella review by Kong, Zhao, Zhang and colleagues synthesized 123 meta-analyses covering 464 outcomes from 5,617 articles to comprehensively assess GLP-1 receptor agonist effectiveness and adverse events across diverse outcomes. Outcomes were grouped into seven categories: endocrine and metabolic, cardiovascular, cancer, renal, respiratory, mortality and adverse events, and other. The review documented improvements in metabolic, cardiovascular, renal, and respiratory outcomes plus cognitive function, with potential reductions in fracture risk and all-cause mortality in selected populations. Increased risks were observed for diabetic retinopathy, ketoacidosis, gastrointestinal events, and treatment discontinuation — useful evidence-summary input for ECO 2026 in Istanbul (May 12–15) and the prevention-trial proposal that 21 obesity-and-cancer experts will present there.
Ahead of the European Congress on Obesity in Istanbul (May 12–15), a 21-expert global panel of obesity and cancer specialists will present a research proposal for a 10-year prospective trial testing GLP-1 receptor agonists like semaglutide and tirzepatide for prevention of obesity-related cancers. The proposal builds on the SELECT trial's established cardiovascular benefit, real-world dementia-incidence reductions, and the broader case that GLP-1s influence multiple aging-driven disease categories. The Istanbul meeting is the same venue where Novo Nordisk will present 52 abstracts on Wegovy, the higher-dose 7.2 mg formulation, the Wegovy pill, and CagriSema, including data on women's obesity, perimenopause, and migraine.